Torstein Valborgland1,2, Kjetil Isaksen3,4, Peter Scott Munk5, Zbigniew Piotr Grabowski6, Alf Inge Larsen3,4. 1. Department of Cardiology, Stavanger University Hospital, Armauer Hansens vei 20, PO Box 8100, 4068, Stavanger, Norway. vtor@sus.no. 2. Department of Clinical Science, University of Bergen, Bergen, Norway. vtor@sus.no. 3. Department of Cardiology, Stavanger University Hospital, Armauer Hansens vei 20, PO Box 8100, 4068, Stavanger, Norway. 4. Department of Clinical Science, University of Bergen, Bergen, Norway. 5. Sørlandet Hospital HF, Kristiansand, Norway. 6. Department of Radiology, Stavanger University Hospital, Stavanger, Norway.
Abstract
BACKGROUND: The syndrome of heart failure (HF) is characterized by left ventricular dysfunction and a compensatory chronic over activation of the sympathetic nervous system. We wanted to investigate if the beneficial effects of exercise training (ET) in HF patients on optimal medical therapy (OMT) are associated with alterations in cardiac sympathetic activity. METHODS:Cardiac sympathetic activity was evaluated at baseline and after 12 weeks using metaiodobenzylguanidine scintigraphy in 23 patients with stable HF participating in the SmartEx trial. Patients with HF in New York Heart Association class II or III and left ventricular ejection fraction <35 % were randomized to three different ET groups. RESULTS: We found no statistically significant changes in cardiac sympathetic activity after 12 weeks of ET. Heart to mediastinum (H/M) ratio at 15 minutes (0.00174 ± 0.0841, P = 0.922), H/M ratio at 4 hours (-0.00565 ± 0.1163, P = 0.818) and washout ratio (WR) (-1.2666 ± 16.5412, P = 0.717). A further group-wise analysis of the three ET groups did not show any difference between the groups. CONCLUSION: A 12-week ET program did not alter the abnormal cardiac sympathetic activity in stable HF patients on modern OMT.
RCT Entities:
BACKGROUND: The syndrome of heart failure (HF) is characterized by left ventricular dysfunction and a compensatory chronic over activation of the sympathetic nervous system. We wanted to investigate if the beneficial effects of exercise training (ET) in HF patients on optimal medical therapy (OMT) are associated with alterations in cardiac sympathetic activity. METHODS: Cardiac sympathetic activity was evaluated at baseline and after 12 weeks using metaiodobenzylguanidine scintigraphy in 23 patients with stable HF participating in the SmartEx trial. Patients with HF in New York Heart Association class II or III and left ventricular ejection fraction <35 % were randomized to three different ET groups. RESULTS: We found no statistically significant changes in cardiac sympathetic activity after 12 weeks of ET. Heart to mediastinum (H/M) ratio at 15 minutes (0.00174 ± 0.0841, P = 0.922), H/M ratio at 4 hours (-0.00565 ± 0.1163, P = 0.818) and washout ratio (WR) (-1.2666 ± 16.5412, P = 0.717). A further group-wise analysis of the three ET groups did not show any difference between the groups. CONCLUSION: A 12-week ET program did not alter the abnormal cardiac sympathetic activity in stable HF patients on modern OMT.
Authors: Khalil Murad; Peter H Brubaker; David M Fitzgerald; Timothy M Morgan; David C Goff; Elsayed Z Soliman; Joel D Eggebeen; Dalane W Kitzman Journal: Congest Heart Fail Date: 2012-04-26
Authors: John J V McMurray; Stamatis Adamopoulos; Stefan D Anker; Angelo Auricchio; Michael Böhm; Kenneth Dickstein; Volkmar Falk; Gerasimos Filippatos; Cândida Fonseca; Miguel Angel Gomez-Sanchez; Tiny Jaarsma; Lars Køber; Gregory Y H Lip; Aldo Pietro Maggioni; Alexander Parkhomenko; Burkert M Pieske; Bogdan A Popescu; Per K Rønnevik; Frans H Rutten; Juerg Schwitter; Petar Seferovic; Janina Stepinska; Pedro T Trindade; Adriaan A Voors; Faiez Zannad; Andreas Zeiher Journal: Eur Heart J Date: 2012-05-19 Impact factor: 29.983
Authors: A Cohen-Solal; Y Esanu; D Logeart; F Pessione; C Dubois; G Dreyfus; R Gourgon; P Merlet Journal: J Am Coll Cardiol Date: 1999-03 Impact factor: 24.094
Authors: Alain Cohen-Solal; François Rouzet; Alain Berdeaux; Dominique Le Guludec; Eric Abergel; André Syrota; Pascal Merlet Journal: J Nucl Med Date: 2005-11 Impact factor: 10.057
Authors: Ferdinando Iellamo; Marco Alfonso Perrone; Andrea Cimini; Giuseppe Caminiti; Agostino Chiaravalloti; Attilio Parisi; Orazio Schillaci Journal: J Cardiovasc Dev Dis Date: 2022-06-05